The burgeoning field of obesity management has witnessed remarkable advancements with the emergence of dual GLP-3 receptor agonists, notably Retatrutide and Trizepatide. These novel therapies represent a significant https://dillanpkpf787361.wssblogs.com/38621960/glp-3-receptor-agonists-retatrutide-trizepatide